A Study Of CP-690,550 In Stable Kidney Transplant Patients

Completed · Phase 1 · Has a placebo group

Conditions studied: Kidney Transplant

In brief

This was a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of 28-day treatment of CP-690,550 in stable renal allograft recipients. In Stage 1, ascending doses of CP-690,550 were to be administered sequentially to 3-4 cohorts of subjects. After Stage 1, one dose level was to be selected for dosing in an expanded cohort in Stage 2.

Key facts

Study ID
NCT01710033
Run by
Pfizer
People needed
28
Starts
2003-09-01
Expected to finish
2005-04-01
Last updated by the study team
2012-12-26

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.